Quantcast

Latest Gene therapy Stories

2014-05-05 12:29:33

MOUNTAIN VIEW, Calif., May 5, 2014 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has partnered with Vectalys SAS to combine Clontech's Living Colors® fluorescent protein and Tet-On® 3G technologies with Vectalys' expertise in providing the highest quality ready-to-use lentiviral particles as vectors for gene delivery. http://photos.prnewswire.com/prnvar/20131021/SF99259LOGO Carol Lou, General Manager of Clontech...

2014-05-05 08:28:53

TARRYTOWN, N.Y. and MENLO PARK, Calif., May 5, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular...

2014-04-29 09:52:38

New research looking at the success of clinical trials of stem cell therapy shows that trials appear to be more successful in studies where there are more discrepancies in the trial data. Researchers from Imperial College London conducted a meta-analysis of 49 randomised controlled trials of bone marrow stem cell therapy for heart disease. The study, published today in the British Medical Journal, identified and listed over 600 discrepancies within the trial reports. Discrepancies were...

2014-04-29 08:36:49

GULF SHORES, Ala., April 29, 2014 /PRNewswire/ -- If successful, Neuralgene's (http://www.neuralgene.com) PRCN-323 treatment could significantly change the prognosis for everyone with the rare genetic disorder known as adrenoleukodystrophy, or ALD. The biotech company has recently celebrated a series of early successes in the treatment of other neurological conditions like ALS (Lou Gehrig's disease). Founder and CEO Jason Williams, M.D., believes his team is on the path toward a cure...

Existing Cochlear Technology Used To Re-grow Auditory Nerves
2014-04-24 03:24:49

[ Watch The Video: Bionic Ear Delivers DNA To Regrow Auditory Nerve Cells ] University of New South Wales Researchers at UNSW Australia have for the first time used electrical pulses delivered from a cochlear implant to deliver gene therapy, thereby successfully regrowing auditory nerves. The research also heralds a possible new way of treating a range of neurological disorders, including Parkinson's disease, and psychiatric conditions such as depression through this novel way...

2014-04-22 12:30:18

- Proceeds will Further Strengthen Avalanche's Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration - MENLO PARK, Calif., April 22, 2014 /PRNewswire/ -- Avalanche Biotechnologies, Inc, a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the successful completion of a $55 million Series B financing. New investors were led by Venrock, and...

2014-04-08 12:30:51

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fv78n3/cardiovascular) has announced the addition of a new report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/fv78n3/cardiovascular ] to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery to the cardiovascular system is different from...

2014-04-08 08:32:20

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/492nrm/gene_therapy) has announced the addition of a new report "Gene Therapy - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/492nrm/gene_therapy ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Gene therapy can be broadly defined as the transfer of defined genetic material to specific target...

2014-04-08 08:32:18

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/t2pjhw/personalized) has announced the addition of a new report "Personalized Medicine - Scientific and Commercial Aspects" [http://www.researchandmarkets.com/research/t2pjhw/personalized ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The aim of personalized medicine or individualized treatment is to match the right drug to...

2014-04-07 16:08:27

The transfer, via a viral vector, of a normal copy of the gene deficient in patients, allowed to fully and very rapidly cure the heart disease in mice. These findings are published in Nature Medicine on 6 April, 2014. Friedreich's ataxia is a severe, rare hereditary disorder which combines progressive neuro-degeneration, impaired heart function and an increased risk of diabetes. The condition affects one in every 50,000 birth. There is currently no effective treatment for this disease. In...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related